Answer Happy

Table 2. Efficacy Calculated with the use of a Cox Proportional-Hazards Model with Baseline Stratification Factors as Covariates.* End Point Remdesivir (N=279) Placebo (N=283) Hazard Ratio (95% CI) P Value 2 (0.7) 15 (5.3) 0.13 (0.03 to 0.59) 0.008 2 (0.7) 15 (5.3) 0.13 0.03 to 0.59) Primary efficacy end point Covid-19related hospitalization or death from any cause by day 28 - no. (%)* Secondary efficacy end points Covid-19-related hospitalization or death from any cause by day 14 — no. (%) Covid-19-related medically attended visit or death from any cause - no./total no. (%) Day 14 Day 28 Death from any cause by day 28 - no. Hospitalization for any cause by day 28 - no. (%) Time-weighted average change in nasopharyngeal 20/252 (7.9) 21/252 (8.3) 2/246 (0.8) 4/246 (1.6) 0 5 (1.8) -1.24 0 0.10 (0.02 to 0.43) 0.19 (0.07 to 0.56) NC 0.28 (0.10 to 0.75) 0.07 (-0.10 to 0.24) 18 (6.4) -1.14
Time-weighted average change in nasopharyngeal -1.24 -1.14 0.07 (-0.10 to 0.24) SARS-CoV-2 viral load from baseline to day 7 logo copies/ml Alleviated baseline Covid-19 symptoms, according to FLU-PRO Plus questionnaire - no./total no. (%) Questionnaire completed before infusion on day 1 23/66 (34.8) 15/60 (25.0) 1.41 (0.73 to 2.69) ** Questionnaire completed on day 1, either before or 61/169 (36.1) 33/165 (20.) 1.92 (1.26 to 2.94) ** after infusion - no./total no. (%)S Baseline stratification factors were residence in a skilled nursing facility (yes or no), age (<60 years or 260 years), and country (United States or outside the United States). Covid-19 denotes coronavirus disease 2019, and NC not calculated. Of the eight patients who were adolescents, none had a Covid-19-related hospitalization or death from any cause by day 28. Data are shown for patients who underwent randomization, received at least one infusion of remdesivir or placebo, and met eligibility cri- teria as defined in protocol amendment 2 or later. The analysis was conducted post hoc. The value is the least-squares mean. On the FLU-PRO (Influenza Patient-Reported Outcome) Plus questionnaire, which was adapted for patients with Covid-19, alleviation of Covid-19 symptoms was defined as mild or absent symptoms. * The value is the rate ratio. The nurse is taking care of a patient in the clinic who has just been diagnosed with Covid-19. The MD prescribes remdesivir to the patient. The patient asks the nurse if it is and effective treatment for COVID. Using Table 2, and your answers from the previous question, how should the nurse answer the patient's question? Include the NNT and the absolute risk reduction numbers in your answer. Make sure your answer is patient friendly with numbers that a patient can use.